A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of Fluad® or Agrippal® in Previously Unvaccinated Healthy Subjects Aged 6 to <36 Months

ovartis Vaccines and Diagnostics S.r.l.0 个研究点开始时间: 2011年1月28日最近更新: 2012年7月17日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Children of 6 to <36 months of age, whose parent(s) or legal guardian(s) have given written informed consent prior to study entry;
•2. Children good health as determined by the outcome of medical history; physical examination and clinical judgment of the investigator;
•3. Children and children’s parent(s) or legal guardian(s) that are able to comply with all study procedures and are available for all clinic visits scheduled in the study.
•4. Willingness to allow for samples to be stored beyond the study period, for potential additional future testing to better characterize immune responses.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study. Routine vaccines, according to local recommendations, or any other vaccines not foreseen in the protocol can be given after the active trial phase (3 weeks after last vaccination) has been concluded;
•2. Receipt of another investigational vaccine or any investigational agent within 30 days prior to enrollment in the study or before completion of the safety follow-up period in another study, whichever is longer, and unwilling to refuse participation in another clinical study through the end of the study;
•3. Experience of a severe acute infectious disease in the month prior to study start or experience of a mild acute infection disease in the week prior the study start (untreated common cold is acceptable);
•4. Any severe acute respiratory disease and infection requiring systemic antibiotic or antiviral therapy ongoing or resolved within 6 days prior to study start;
•5. Experience a body temperature ?38.0°C within the 3 days before enrollment.
•6. Children with history or any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study
•7. Children with known or suspected impairment/alteration of immune function, for example resulting from:
•a. receipt of immunosuppressive therapy such as systemic corticosteroids known to be associated with the suppression of hypothalamic-pituitary-adrenal (HPA) axis (15 mg/day of prednisone or its equivalent) or chronic use of inhaled high-potency corticosteroids (e.g. budesonide 800µg/day or fluticasone 750µg/day) within 60 days prior to Visit 1,
•b. receipt of immunostimulants within 60 days prior to Visit 1,
•c. receipt of parenteral immunoglobulin preparartion, blood products, and/or plasma derivatives within 3 months prior to Visit 1 or planned during the full length of the study,
•d. known HIV infection or HIV-related disease;
•8. Children with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time
•9. History of hypersensitivity to any component of the study medication or chemically related substances;
•10. History of any anaphylaxis, serious vaccine reactions, or allergy to eggs, egg products or any other vaccine component;
•11. Individuals who have had influenza vaccine or documented suspected influenza disease prior to day 1;
•12. History of neurological disorder or seizures (febrile seizures allowed).
•13. Ever received any influenza vaccine.
•14. Major surgery planned during the study period.
•15. Children hospitalized
•16. Children with any fatal prognosis of an underlying medical condition (<12 month life expectancy

研究者

发起方

ovartis Vaccines and Diagnostics S.r.l.

相似试验

进行中（未招募）

1 期

A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of Fluad® or Agrippal® in Previously Unvaccinated Healthy Subjects Aged 6 to <36 Monthsinfluenza

EUCTR2010-023791-63-BEovartis Vaccines and Diagnostics S.r.l.

进行中（未招募）

1 期

A study to find out if a vaccine designed to protect against a disease (group B meningococcal meningitis) is safe and protects toddlers aged 12 <18months or 18 < 24 months.Invasive meningococcal disease (IMD) caused by Neisseria meningitidisserogroup BMedDRA version: 20.0Level: PTClassification code 10027249Term: Meningitis meningococcalSystem Organ Class: 10021881 - Infections and infestations

EUCTR2011-004400-38-PLPfizer Inc, 235 East 42nd Street, New York, NY 10017396

进行中（未招募）

1 期

EUCTR2011-004400-38-CZPfizer Inc396

进行中（未招募）

1 期

EUCTR2011-004400-38-FIPfizer Inc, 235 East 42nd Street, New York, NY 10017396

进行中（未招募）

不适用

A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Subjects aged 6 months to 17 yearsMedDRA version: 9.1Level: LLTClassification code 10064097Term: Avian influenzaavian influenza

EUCTR2007-002480-27-FIovartis Vaccines and Diagnostics GmbH & Co. KG